tbuckley/cabot-search huggingface dataset:
Spinal cord stimulation in heart failure: effect on disease‐associated biomarkers
Authors: Jan Naar, Deborah Jaye, Cecilia Linde, Petr Neužil, Petr Doškář, Filip Málek, Frieder Braunschweig, Lars H. Lund, Lars Mortensen, Magnus Bäck, Bengt Linderoth, Göran Lind, Fred Kueffer, Jodi Koehler, Kambiz Shahgaldi, Marcus Ståhlberg
Journal: European Journal of Heart Failure (2017)
Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group,
Authors: Michael R. Loken, Todd A. Alonzo, Laura Pardo, Robert B. Gerbing, Richard Aplenc, Lillian Sung, Susana C. Raimondi, Betsy A. Hirsch, Samir Kahwash, Amy Heerema-McKenney, Laura Winter, Kathleen Glick, Patti Byron, Laura Fransisco, Tanya Wallas, Stella M. Davies, Franklin O. Smith, Alan S. Gamis, Soheil Meshinchi
Journal: Blood (2011)
Comparable Results of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia in First Complete Molecular Remission: An Analysis By the Acute Leukemia Working Party of the EBMT
Authors: Sebastian Giebel, Myriam Labopin, Michael Potter, Xavier Poiré, Henrik Sengeloev, Gerard Socié, Anne Huynh, Boris V Afanasyev, Urs Schanz, Olle Ringden, Peter Kalhs, Dietrich W. Beelen, Antonio M. Campos, Tamás Masszi, Mohamad Mohty, Arnon Nagler*
Journal: Blood (2016)
Prognostic Effect of ASXL1 Mutations in Patients with MDS and Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Christian Koenecke, Felicitas Thol, Patrick Löffeld, Stefanie Buchholz, Michael Stadler, Gudrun Göhring, Elke Dammann, Moritz Kleine, Wiebke Brauns, Michael Hallensleben, Jörg Schmidtke, Brigitte Schlegelberger, Jürgen Krauter, Arnold Ganser, Michael Heuser
Journal: Blood (2011)
Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies
Authors: Cecilia Y Arana Yi, Hagop M. Kantarjian, Guillermo Garcia-Manero, William G. Wierda, Gautam Borthakur, Alfonso Quintas-Cardama, Marina Konopleva, Stefan Faderl, Sherry A. Pierce, Michael Andreeff, Farhad Ravandi, Jorge E. Cortes
Journal: Blood (2012)
Molecular Mechanisms of NF-kappaB Activation by the HTLV-I Oncoprotein Tax: Role of Post Translational Protein Modification.
Authors: Youmna Kfoury, Rihab Nasr, Arnaud Favre-Bonvin, Marwan El-Sabban, Noemie Renault, Marie-Louise Giron, Hiba El Hajj, Estelle Chiari, Abdul Ghani Mikati, Olivier Hermine, Ali Saib, Hugues de Thé, Claudine Pique, Ali Bazarbachi
Journal: Blood (2007)
Impact of Human Leukocyte Antigen Compatibility on Engraftment in Adult Patients Receiving Reduced-Intensity Umbilical Cord Blood Transplantation Using Calcineurin Inhibitor Alone for GVHD Prophylaxis.
Authors: Naofumi Matsuno, Atsushi Wake, Naoyuki Uchida, Shinsuke Takagi, Daisuke Kato, Yoshiko Matsuhashi, Sachiko Seo, Kazuhiro Masuoka, Shigesaburo Miyakoshi, Michio Matsuzaki, Akiko Yoneyama, Shuichi Taniguchi
Journal: Blood (2006)
The role of exosomes in the pathogenesis of Alzheimer’ disease
Authors: Tingting Xiao, Weiwei Zhang, Bin Jiao, Chu-Zheng Pan, Xixi Liu, Lu Shen
Journal: Translational Neurodegeneration (2017)

Exosomes are small vesicles secreted by most cell types including neurons that function in intercellular communication through transfer of their cargo or encapsulate and eliminate unnecessary cellular components and therefore have a broad impact on nerve development, activation and regeneration. In addition, exosomes have been observed to be involved in spreading pathological misfolded proteins, thereby leading to the onset and propagation of disease. Alzheimer disease (AD) is the most common form of dementia and characterized by two types of lesions: amyloid plaques and neurofibrillary tangles. Accumulating evidence has demonstrated that exosomes are associated with amyloid precursor (APP) and Tau proteins and play a controversial role in Alzheimer's disease process. In this review, we will discuss the role of exosomes in the metabolism and secretion of APP and Tau proteins and their subsequent impact on AD pathogenesis.
Phase I/II Study of Escalating Doses of Idarubicin Orally Given with Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patients with Disseminated High Grade Non Hodgkin Lymphoma.
Authors: Amélie Fauveau, Laurence Lacotte-Thierry, Emmanuel Fleck, Jean Yves Colin, François Guilhot, Michèle Chabin, Alice Langlois, Joëlle Guilhot, Vincent Delwail
Journal: Blood (2009)
No Association of Fish and Omega-3 Fatty Acid Intake with Coronary Calcification : The Rotterdam Coronary Calcification Study
Authors: Renate C. Broring, Ingeborg A. Brouwer, Rozemarijn Vliegenthart, Frank J. van Rooij, Jacqueline C. Witteman, Johanna M. Geleijnse
Journal: Circulation (2009)
A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma
Authors: Ajay K. Gopal, Ted A. Gooley, Joseph Rajendran, John M. Pagel, Darrell R. Fisher, David G. Maloney, Frederick R. Appelbaum, Andrew Shields, Damian J. Green, Oliver W. Press
Journal: Blood (2012)
Molecular Genetic Characterization of 3'-Deletion of MLL Gene in Infant Acute Leukemia.
Authors: Grigory Tsaur, Olga Plekhanova, Alexander Popov, Tatyana Gindina, Yulia Olshanskaya, Alena Volochnik, Anna Kazakova, Anatoly Kustanovich, Irina Martynkevich, Liudmila Martynenko, Elena Matveeva, Vanik Ovsepyan, Tatyana Riger, Leonid Saveliev, Egor Shorikov, Elena Fleishman, Olga Sokova, Claus Meyer, Rolf Marschalek, Larisa Fechina
Journal: Blood (2012)
The Role of Annexin II in Stem Cell Homing to Endosteal Osteoblasts - Molecular Dissection of the Hematopoietic Stem Cell Niche.
Authors: Russell S. Taichman, Younghun Jung, Jingcheng Wang, Junhui Song, Jianhua H. Wang, Aaron Havens, Yanxi X. Sun, Paul H. Krebsbach
Journal: Blood (2005)
Hospital readmissions for COPD in England are rising, audit shows
Authors: Gareth Iacobucci
Journal: BMJ (2017)

The number of hospital readmissions among people with chronic obstructive pulmonary disease (COPD) rose by almost a third from 2008 to 2014, an analysis has shown.1

The latest National COPD Audit Programme report from the Royal College of Physicians showed that, in 2014, 43% of patients in England who were admitted for hospital treatment of COPD were readmitted at least once in the three months after discharge. This represents a considerable increase from the 33% readmission rate reported in the last audit in 2008.2

The college said that the current system was failing COPD …
Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.
Authors: Noopur Raje, Teru Hideshima, Sonia Vallet, Diana Cirstea, Tanyel Kiziltepe, Shweta Chhetri, Mala Mani, Siddhartha Mukherjee, Daniel Ruben Carrasco, Constantine Mitsiades, Melissa Rooney, Klaus Podar, Yutaka Okawa, Hiroshi Ikeda, Paul G. Richardson, Dharminder Chauhan, Nikhil C. Munshi, Somesh Sharma, Himanshu Parikh, Bruce Chabner, Kenneth C. Anderson
Journal: Blood (2007)
A pilot study evaluating surrogates of response to short-term vorinostat in women with newly diagnosed breast cancer
Authors: V. Stearns, L. K. Jacobs, T. N. Tsangaris, S. Briest, J. R. Lange, S. Slater, M. Fackler, E. Sugar, E. Gabrielson, N. E. Davidson
Journal: Journal of Clinical Oncology (2009)

e14508 Background: Epigenetic modifications contribute to breast cancer initiation and progression and may be reversible, thus representing an attractive area for new drug investigation. In preclinical breast cancer models, the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA, vorinostat) induces cell cycle arrest, apoptosis and differentiation. Methods: We evaluated the safety and tolerability of short term vorinostat in women with a primary clinical stage I-III histologically confirmed carcinoma of the breast on a core needle biopsy. Participants received vorinostat 300 mg PO bid for a total of 6 doses, the last dose 2 hours prior to surgery or biopsy. Peripheral blood mononuclear cells were collected at baseline and following the last vorinostat dose to determine histone acetylation. Baseline and post-treatment tumor specimens were collected for analysis of histone acetylation, candidate gene methylation and expression. Tissues were also collected from untreated controls. Paired t-tests and Fisher's exact tests were used to evaluate changes from baseline for continuous and categorical data, respectively. Results: From March 2006 to October 2008, 25 women signed an informed consent and initiated study drug. Median age was 55 and 80% had hormone receptor positive tumors. Twenty-two women took all 6 prescribed doses. One participant took 4 and one 5 doses due to insurance clearance delay; one received a single dose due to fatigue and abdominal pain. Study-related surgical delays did not occur. Grade 1 toxicities included diarrhea (28%), low white blood cell count (24%), and fatigue, taste alterations and nausea (16% each). Tissue and blood samples were successfully collected. Tissue was also collected from 25 untreated controls. No significant change was observed in the proliferation marker Ki67 following 3 days of agent administration. Modulation of apoptosis, histone acetylation and gene methylation will be presented. Conclusions: Short-term administration of vorinostat is feasible, safe, and allows for studies of biomarker modulation. The results will be used to design future studies in which vorinostat will be administered in combination with other targeted therapies or with other epigenetic modifiers. [Table: see text]
Poly-sgRNA/siRNA ribonucleoprotein nanoparticles for targeted gene disruption
Authors: Jong Seong Ha, Jae Sung Lee, Jaepil Jeong, Hejin Kim, Juyoung Byun, Sang Ah Kim, Hee Jae Lee, Hak Suk Chung, Jong Bum Lee, Dae-Ro Ahn
Journal: Journal of Controlled Release (2017)
Increased Mitochondrial Gene Deletions and ROS Production in Transgenic Mice Overexpressing a Human 8-Oxoguanine DNA-Glycosylase Gene: A Causal Association with the Development of Hematopoietic Neoplasms
Authors: Qin Huang, Haihong Zhang, Wei Chen, Serhan Alkan, Chunyang Fan
Journal: Blood (2014)
Frequency and Natural History of Inherited Bone Marrow Failure Syndromes: The Israeli Inherited Bone Marrow Failure Registry
Authors: Hannah Tamary, Daniella Nishri, Joanne Yacobovich, Rama Zilber, Shraga Aviner, Polina Stepensky, Shoshana S Vilk- Ravel, Menachem Bitan, Chaim Kaplinsky, Ayelet Ben Barak, Joseph Kapelusnik, Ariel Koren, Carina Levin, Isaac Yaniv, Philip S Rosenberg, Blanche P. Alter
Journal: Blood (2008)
Myocardial fibrosis: biomedical research from bench to bedside
Authors: Mariann Gyöngyösi, Johannes Winkler, Isbaal Ramos, Quoc‐Tuan Do, Hüseyin Firat, Kenneth McDonald, Arantxa González, Thomas Thum, Javier Díez, Frédéric Jaisser, Anne Pizard, Faiez Zannad
Journal: European Journal of Heart Failure (2017)

Myocardial fibrosis refers to a variety of quantitative and qualitative changes in the interstitial myocardial collagen network that occur in response to cardiac ischaemic insults, systemic diseases, drugs, or any other harmful stimulus affecting the circulatory system or the heart itself. Myocardial fibrosis alters the architecture of the myocardium, facilitating the development of cardiac dysfunction, also inducing arrhythmias, influencing the clinical course and outcome of heart failure patients. Focusing on myocardial fibrosis may potentially improve patient care through the targeted diagnosis and treatment of emerging fibrotic pathways. The European Commission funded the FIBROTARGETS consortium as a multinational academic and industrial consortium with the primary aim of performing a systematic and collaborative search of targets of myocardial fibrosis, and then translating these mechanisms into individualized diagnostic tools and specific therapeutic pharmacological options for heart failure. This review focuses on those methodological and technological aspects considered and developed by the consortium to facilitate the transfer of the new mechanistic knowledge on myocardial fibrosis into potential biomedical applications.
Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.
Authors: J. Brice Weinberg, Ning Jiang, Alicia D. Volkheimer, Youwei Chen, Karen M. Bond, Joseph O. Moore, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, David A. Rizzieri, Marc C. Levesque, Kenneth Mugridge, Joe DeAngelo
Journal: Blood (2007)
PTPS-25NANOPARTICLE DELIVERY FOR THE TREATMENT OF PONTINE GLIOMAS
Authors: Harini Rao, Mark Saltzman
Journal: Neuro-Oncology (2015)

BACKGROUND: Malignant brain tumors in children younger than age 15 years account for ∼ 20% of brain tumors. Brain tumor therapy is currently limited in terms of the number of drugs and drug delivery systems to which can be applied. Development of delivery systems is disadvantaged by the availability of suitable models for studying such systems in vitro. A major limitation to pediatric brain tumors is the blood brain barrier. Development in the neuro-oncology field has shown some advancement in treating brain tumors using local delivery mechanisms. Unresectable brain tumors, such as pontine gliomas, do not have known effective long-term therapy. By applying convection delivery mechanisms, these unresectable brain tumors may show some response to targeted delivery. OBJECTIVE: To devise a delivery system to directly target pontine gliomas with nanoparticles via convection enhanced delivery. DESIGN/METHOD: Nanoparticles are developed using a standard method to encapsulate chemotherapeutic agents. A mouse model glioma cell line, NP53 and a glioblastoma (GBM) cell line, U-87 are used to determine drug alone versus nanoparticle encapusated drug. Carboplatin is currently the drug being tested using cell titer assays in order to obtain cell viability when treated with the drug-nanoparticle combination. RESULTS: Dose responses are observed when testing the cell lines with drug alone and drug encapsulated nanoparticles. CONCLUSION: Encapsulated chemotherapeutic agents, such as Carboplatin can be used to directly target pontine gliomas. Glioma cell lines and GBM cell lines have shown cell death with administration of nanoparticles.
Vascular Risk Factors and Diabetic Neuropathy
Authors: Solomon Tesfaye, Nish Chaturvedi, Simon E.M. Eaton, John D. Ward, Christos Manes, Constantin Ionescu-Tirgoviste, Daniel R. Witte, John H. Fuller
Journal: New England Journal of Medicine (2005)

Other than glycemic control, there are no treatments for diabetic neuropathy. Thus, identifying potentially modifiable risk factors for neuropathy is crucial. We studied risk factors for the development of distal symmetric neuropathy in 1172 patients with type 1 diabetes mellitus from 31 centers participating in the European Diabetes (EURODIAB) Prospective Complications Study.
Decitabine (DAC) Can Be Safely Reduced After Achievement of Best Response In Patients (pts) with Myelodysplastic Syndrome (MDS)
Authors: A. Megan Cornelison, Guillermo Garcia Manero, Hagop Kantarjian, Farhad Ravandi, Tapan Kadia, Jorge Cortes, Susan O'Brien, Gautam Borthakur, Mark Brandt, Elias J Jabbour
Journal: Blood (2010)
Arsenic Trioxide Inhibited Bacterial Growth but Increased the Incidence of Herpes Zoster among Patients with APL; Results from In Vitro and Clinical Studies.
Authors: Akihiro Takeshita, Kaori Shinjo, Kazuyuki Shigeno, Naohi Sahara, Takaaki Ono, Satoki Nakamura, Masato Maekawa, Kazunori Ohnishi, Ryuzo Ohno
Journal: Blood (2006)
Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions
Authors: Alba Matas-Céspedes, Anna Vidal-Crespo, Vanina Rodriguez, Julio Delgado, Neus Villamor, Gael Roue, Elías Campo, Dolors Colomer, Parul Doshi, Adrian Wiestner, Paul W.H.I. Parren, Jeroen Lammerts van Bueren, Patricia Pérez-Galán
Journal: Blood (2014)
Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer
Authors: Natalie J. Engmann, Marzieh K. Golmakani, Diana L. Miglioretti, Brian L. Sprague, Karla Kerlikowske
Journal: JAMA Oncology (2017)

Many established breast cancer risk factors are used in clinical risk prediction models, although the proportion of breast cancers explained by these factors is unknown.To determine the population-attributable risk proportion (PARP) for breast cancer associated with clinical breast cancer risk factors among premenopausal and postmenopausal women.Case-control study with 1:10 matching on age, year of risk factor assessment, and Breast Cancer Surveillance Consortium (BCSC) registry. Risk factor data were collected prospectively from January 1, 1996, through October 31, 2012, from BCSC community-based breast imaging facilities. A total of 18 437 women with invasive breast cancer or ductal carcinoma in situ were enrolled as cases and matched to 184 309 women without breast cancer, with a total of 58 146 premenopausal and 144 600 postmenopausal women enrolled in the study.Breast Imaging Reporting and Data System (BI-RADS) breast density (heterogeneously or extremely dense vs scattered fibroglandular densities), first-degree family history of breast cancer, body mass index (>25 vs 18.5-25), history of benign breast biopsy, and nulliparity or age at first birth (≥30 years vs <30 years).Population-attributable risk proportion of breast cancer.Of the 18 437 women with breast cancer, the mean (SD) age was 46.3 (3.7) years among premenopausal women and 61.7 (7.2) years among the postmenopausal women. Overall, 4747 (89.8%) premenopausal and 12 502 (95.1%) postmenopausal women with breast cancer had at least 1 breast cancer risk factor. The combined PARP of all risk factors was 52.7% (95% CI, 49.1%-56.3%) among premenopausal women and 54.7% (95% CI, 46.5%-54.7%) among postmenopausal women. Breast density was the most prevalent risk factor for both premenopausal and postmenopausal women and had the largest effect on the PARP; 39.3% (95% CI, 36.6%-42.0%) of premenopausal and 26.2% (95% CI, 24.4%-28.0%) of postmenopausal breast cancers could potentially be averted if all women with heterogeneously or extremely dense breasts shifted to scattered fibroglandular breast density. Among postmenopausal women, 22.8% (95% CI, 18.3%-27.3%) of breast cancers could potentially be averted if all overweight and obese women attained a body mass index of less than 25.Most women with breast cancer have at least 1 breast cancer risk factor routinely documented at the time of mammography, and more than half of premenopausal and postmenopausal breast cancers are explained by these factors. These easily assessed risk factors should be incorporated into risk prediction models to stratify breast cancer risk and promote risk-based screening and targeted prevention efforts.
Combination of Rituximab, Bortezomib and Hyper-Fractionated Cyclophosphamide (RBC) in “True” Elderly Patients with Advanced Mantle Cell Lympoma.
Authors: Roberto Guariglia, Giuseppe Pietrantuono, Oreste Villani, Maria Carmen Martorelli, Fiorella D’Auria, Angela Zupa, Gabriella Bianchino, Vitina Grieco, Luigina Digiovannantonio, Alessandra Benvenuto, Elisa Feudale, Antonello Pinto, Felicetto Ferrara, Pellegrino Musto
Journal: Blood (2007)
Gene Expression Analysis of Leukemic Blasts Persisting at Day 8 of Induction Therapy in Childhood ALL.
Authors: Peter Rhein, Richard Ratei, Stefanie Scheid, Christian Hagemeier, Karl Seeger, Renate Kirschner, Martin Schrappe, Rainer Spang, Wolf-Dieter Ludwig, Leonid Karawajew
Journal: Blood (2004)
DOES HIGHER COMPLIANCE TO THE FIFA 11+ INJURY PREVENTION PROGRAM IMPROVE OVERALL INJURY RATE IN MALE SOCCER (FOOTBALL) PLAYERS?
Authors: Holly Silvers-Granelli, Mario Bizzini, Amy Arundale, Bert Mandelbaum, Ryan Pohlig, Lynn Snyder-Mackler
Journal: British Journal of Sports Medicine (2017)

Background The FIFA 11+ program can decrease the rate of injury in athletes. Few studies have investigated the role of compliance and if it is correlated to time loss due to injury during a season. Objective (1) Analyze how differences in compliance to the FIFA 11+ (IP) program may impact injury rate and (2) how differences in program compliance may impact time loss due to injury. Design Prospective cohort RCT. Setting Division I &amp; II Men's Soccer (USA). Patients (or Participants) Sixty-one Division I and II Men's soccer teams were followed over one competitive season. Injury rates and time loss were analyzed. Twenty-seven teams (N=675 players) served as the intervention group (IG) using the FIFA 11+. Interventions (or Assessment of Risk Factors) Compliance to the IP program and injuries were collected weekly using a secure internet-based system. Main Outcome Measurements Compliance, exposure and injuries were recorded in 27 of 61 male soccer teams. Results There was an overall reduction of injury in the IG by 46.1%; demonstrating the decreased likelihood of being injured (RR =0.54, 95% CI 0.49 to 0.59, p&lt;0.0001, NNT=2.64). Compliance was stratified by utilization consistency: low (LC: 1–19 doses/season), moderate (MC: 20–39 doses/season), or high (HC: &gt;40 doses per season). The average utilization per team was 32.81±12.06 FIFA 11+ sessions. There were 54 injuries in 4 teams reported in the LC group (M=13.5, range 10–19 doses, IR=10.35±2.21), 156 injuries in 14 teams in the MC (M=11.14, range 21–39 doses, IR=8.55±2.46) and 75 injuries in 9 teams in the HC group (M=8.33, range 40–64 doses, IR=6.39±2.71). There was a statistically significant difference reached between compliance and injury rate (p=0.034). Conclusions When compliance to the IP was high, there was a significant reduction in injury and time loss compared to the MC and LC.
CBIO-27TUMOR SUPPRESSION EFFECT OF mir-29b IN GLIOBLASTOMA
Authors: Jaekyung Shin, Ja Eun Kim, Chul-Kee Park
Journal: Neuro-Oncology (2015)

Glioblastoma (GBM) is known as one of the most fatal forms of cancer.MicroRNAs have been widely implicated in the regulation of mammalian development and its pathogenesis.The brain-enriched miR-29 subfamilies are known to be exclusively expressed in the developing brain, while, they are aberrantly down-regulated in brain tumors.Besides, the mechanisms by which miR-29 mediated signal components in brain neoplasms remain undetermined.This study aims to elucidate the role of miR-29b in GBM development and the feasibility of therapeutic target using conjugated nanoparticles.We have discovered that increase in apoptotic cell populations with introduction of miR-29b in A172, a PTEN-deficient GBM cell line.An established human-derived GBM tissue slice culture system confirmed the anticancer effect of the miR-29b-conjugated-nanoparticle.Using PCR array, we found that exogenous miR-29b inhibit SPARC (secreted protein acidic and rich in cysteine) expression which mediates anticancer effect.The suppression of miR-29b regulates SPARC and contributes tumor development in GBM.Introduction of miR-29b using nanoparticle-delivery system can be considered as putative therapeutic strategy in GBM.